All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Recombinant adenovirus is one of the most widely used gene delivery vectors for gene therapy, vaccine, and virus therapy applications. However, the production of recombinant adenovirus usually takes two to three weeks and thereby is still a time-consuming and laborious process. Creative Biolabs has developed an AdStable™ stable PCL platform for rapid production and amplification of adenovirus. Through a proprietary packaging and producer cell lines optimization strategy, our PCL platform enables high-performance virus vector production from preclinical research-grade and smaller amounts up to large scale production in significantly reduced timelines. Besides, our PCL platform enables consistent quality virus delivery, cost-effective manufacturing, and minimize process risks. No need for helper viruses, expensive transfection reagents, or cGMP-grade plasmids. Just propagate our packaging cell lines and switch on production.
Creative Biolabs' proprietary AdStable™ technology based on human suspension cells is specifically designed for the production of RCA-free adenovirus vectors. It is an ideal and highly scalable production platform for the production of adenovirus vectors from research grade to smaller batches to industrial scale.
In addition to adenoviral vectors, AdStable™ has also been proven to be an effective host cell line for the production of viral vaccines, lentiviral vectors, oncolytic viruses, and exosomes.
Non-tumor cell line derived from human amniocytes
Complete documentation of cell line development and full certification of materials
Suspension cell line growing at high cell densities for high yields
GMP MCB tested according to ICH guidelines and WHO recommendations
Our goal is to provide superior product depth and expertise to help companies develop breakthrough therapies. If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION